| Gene Symbol | ent-gene-28e2cb01 |
| Phagocytosis | TREM2 signaling enhances clearance of debris, apoptotic cells, and protein aggregates |
| Cytokine regulation | Modulates production of inflammatory cytokines including IL-6, TNF-α, and IL-1β |
| Metabolic adaptation | Supports microglial lipid metabolism and mitochondrial function |
| Cell survival | Provides pro-survival signaling through AKT activation |
| [TREM2](/genes/trem2) variants | While TREM2 R47H is strongly associated with AD risk, evidence for ALS is weaker |
| [TYROBP](/genes/tyrobp) | Genetic variants in the TREM2 signaling adaptor show nominal association with ALS |
| Gene expression | Single-cell RNA-seq studies show altered TREM2 expression in ALS microglia |
| TREM2 knockout mice | Show altered microglial responses in ALS models |
| TREM2 agonism | Preclinical studies suggest TREM2-activating antibodies may enhance neuroprotection |
| C9orf72 connection | The C9orf72 gene (most common ALS cause) regulates lysosomal function, potentially linking to TREM2-mediated phagocytosis |
| Timing | Optimal intervention window (presymptomatic vs. symptomatic) unclear |
| Biomarker need | No validated biomarkers for TREM2 pathway activity in ALS patients |
| Safety concerns | Over-activation could exacerbate neuroinflammation |
| Patient selection | Which ALS subtypes would benefit most from TREM2-targeted therapy |
| KG Connections | 94 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |
No AI portrait yet
No comments yet. Be the first to comment!